Mindstate Design Labs, a Y Combinator-backed startup, has received FDA and EMA approval for human trials of its unique psychedelic compound, MSD-001. This compound, designed to be ‘tofu-like’ in its effects, allows for precise tailoring of altered states of consciousness through the use of ‘probes’. Mindstate’s AI platform, Osmanthus, analyzes a massive dataset of drug reports to create these customized experiences, potentially revolutionizing the treatment of mental health conditions.